Paraproteinaemia / monoclonal protein work-up
paraprotein w/u · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Detection of a monoclonal immunoglobulin requires determining whether it represents benign MGUS or an underlying plasma cell or lymphoproliferative malignancy, and whether the paraprotein itself is causing organ damage.
Red flags
- CRAB features (hypercalcaemia, renal impairment, anaemia, bone lesions)
- Nephrotic-range proteinuria or cardiac failure (amyloid)
- Hyperviscosity (IgM paraprotein)
- Rapidly rising paraprotein
- Peripheral neuropathy with paraprotein
Assessment
Differential diagnosis
- MGUS
- Multiple myeloma
- Waldenstrom macroglobulinaemia
- AL amyloidosis
- Smouldering myeloma
- Lymphoma / CLL-associated paraprotein
Investigations
- Serum protein electrophoresis and immunofixation; paraprotein quantification
- Serum free light chains and ratio
- FBC, calcium, renal function, albumin
- Beta-2 microglobulin and immunoglobulin levels (immunoparesis)
- Urine for Bence Jones protein
- Skeletal imaging (low-dose CT/MRI) and marrow if myeloma suspected
Management
- Characterise the paraprotein type and concentration
- Assess for end-organ damage: the CRAB features (calcium, renal, anaemia, bone)
- Quantify free light chains and look for immunoparesis
- Stratify risk by paraprotein size, isotype (non-IgG higher risk) and light chain ratio
- Diagnose MGUS when criteria met without myeloma-defining events
- Investigate further (marrow, imaging) when risk factors or organ damage present
- Consider amyloidosis if proteinuria, cardiac or neuropathic features
- Consider Waldenstrom/lymphoma for IgM paraproteins with lymphoproliferative features
- Set a surveillance schedule for MGUS based on risk category
- Refer to haematology for high-risk, symptomatic or progressive disease
Drugs & doses
No treatment for asymptomatic MGUS - surveillance only
Treat underlying malignancy if diagnosed (see myeloma/lymphoma protocols)
Bone protection and supportive care if myeloma confirmed
Disposition
Primary care/haematology surveillance for low-risk MGUS; haematology referral for high-risk or symptomatic paraproteinaemia.
Complications & pitfalls
- Progression of MGUS to myeloma/lymphoma
- AL amyloidosis
- Renal impairment (light chain / cast nephropathy)
- Hyperviscosity syndrome
- Pathological fractures if malignant
Exam pearls
- MGUS carries roughly 1% annual progression risk - lifelong surveillance
- Non-IgG isotype, high paraprotein and abnormal light chain ratio raise progression risk
- IgM paraproteins point toward Waldenstrom/lymphoma, not myeloma
- Suspect amyloidosis with proteinuria, cardiomyopathy or neuropathy
- Free light chains are key for both diagnosis and monitoring
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.